Otsuka Novel Products GmbH
Acronym: ONPG
General Information
Identification Code: 260256215861-19
Website: [object Object]
Entity Form: GmbH
Registration Category: Companies & groups
Registration Date: 2/2/2015
Last Update: 11/3/2023
EP Accredited Number: 0
Mission & Interests
Goals: Otsuka Novel Products GmbH (ONPG), based in Munich, Germany, was founded by the global Otsuka-group in 2011. The main focus of the company is the therapeutic area of tuberculosis.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Communication
- Foreign affairs and security policy
- Humanitarian aid and civil protection
- International co-operation and development
- Public health
- Research and innovation
Levels of Interest:
- global
Activities
Main EU Legislative Proposals: - Commission's Communication on a One-Health Action Plan to support Member States in the fight against Antimicrobial Resistance (AMR)
- Agenda 2030 for Sustainable Development
- Tuberculosis Action Plan for the WHO European Region 2023-2030
Communication Activities: It is Otsuka Novel Products GmbH goal to increase awareness of Global tuberculosis pandemic, to improve access to diagnostic und medicines, rapid and equitable access to pharmaceuticals worldwide. Therefore, Otsuka is working with industry partners, governments, NGOs, health agencies in tuberculosis high burden countries.
1. Otsuka is member of EU Patient-Centric Clinical Trial Platforms EU PEARL - https://www.eu-pearl.eu/
This project is funded by the Innovative Medicines Initiative (IMI), a large, far-reaching public-private partnership integrated by the European Union and the pharmaceutical industry to support research and innovation in life-science.
EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a tested and trusted framework for patient-centric integrated research platform (IRP) trials, through which novel techniques and treatments developed by multiple companies and organizations are tested in a platform trial.
2. Otsuka is member of the Antimicrobial Resistance initiative (AMR) - https://www.amrindustryalliance.org/
The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces. Antimicrobial resistance poses a formidable threat to the attainment of the Sustainable Development Goals (SDGs). The United Nations called in 2016 for concerted action from governments and various sectors to address the implications of antimicrobial resistance in a comprehensive manner, and implement strategies at national level.
The AMR Industry Alliance is the life-sciences industry response to the call for action.
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: Erika-Mann-Str. 21
Post Code: 80636
City: München
Country: GERMANY
Phone: [object Object]
EU Office
Address: Erika-Mann-Str. 21
Post Code: 80636
City: München
Country: GERMANY
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Membership Information
Members10 Percent: 0
Members25 Percent: 6
Members50 Percent: 0
Members75 Percent: 0
Members: 6
Members F T E: 1.5
Structure
Structure Type: Structure
Is Member Of: https://www.eu-pearl.eu/
https://www.amrindustryalliance.org/
https://www.unite4tb.org/
Organisation Members: https://www.eu-pearl.eu/
https://www.amrindustryalliance.org/
https://www.unite4tb.org/